Home Newsfeeds Benchmark Initiates Coverage On Landstar System with Hold Rating

Benchmark Initiates Coverage On Landstar System with Hold Rating

Benchmark analyst Christopher Kuhn initiates coverage on Landstar System (NASDAQ:LSTR) with a Hold rating.

byBenzinga Newsdesk

August 31, 2022

1 minute read

Benchmark analyst Christopher Kuhn initiates coverage on Landstar System (NASDAQ:LSTR) with a Hold rating.

Evercore ISI Group Upgrades Spero Therapeutics to Outperform, Raises Price Target to $8

By Benzinga Newsdesk

September 23, 4:42 AM

Evercore ISI Group analyst Josh Schimmer upgrades Spero Therapeutics (NASDAQ:SPRO) from In-Line to Outperform and raises the price target from $2 to $8.

SPRO

KB Home Flexes Financial Muscle: Approves $1B Stock Repurchase Plan & 25% Dividend Hike

By Shivani Kumaresan

April 19, 8:21 AM

KB Home said its Board of Directors authorized the repurchase of up to $1.00 billion of the company's outstanding common stock. The Board also approved an increase in the quarterly cash dividend on the stock to $0.25 per share from $0.20 per share.

KBH

Amkor Technology Q4 EPS $0.67 Misses $0.70 Estimate, Sales $1.91B Beat $1.85B Estimate

By Happy Mohamed

February 13, 5:04 PM

Amkor Technology (NASDAQ:AMKR) reported quarterly earnings of $0.67 per share which missed the analyst consensus estimate of $0.70 by 4.29 percent. This is a 23.86 percent decrease over earnings of $0.88 per share from

AMKR

Inspire Medical’s Recovery from Temporary Q3 Revenue Shortfall – Analysts Find Optimism

By Vandana Singh

November 8, 4:21 PM

Tuesday, Inspire Medical Systems Inc (NYSE: INSP) released Q3 earnings, with sales of $153.3 million, up 40% Y/Y, beating the

INSP

Benchmark Initiates Coverage On Landstar System with Hold Rating

Related Posts

Evercore ISI Group Upgrades Spero Therapeutics to Outperform, Raises Price Target to $8

KB Home Flexes Financial Muscle: Approves $1B Stock Repurchase Plan & 25% Dividend Hike

Amkor Technology Q4 EPS $0.67 Misses $0.70 Estimate, Sales $1.91B Beat $1.85B Estimate

Inspire Medical’s Recovery from Temporary Q3 Revenue Shortfall – Analysts Find Optimism